Tarazi R C, Dustan H P, Bravo E L
Postgrad Med J. 1976;52 Suppl 4:92-100.
Like hypertension which is a multifactorial disease, the blood pressure response to propranolol cannot be explained by one mechanism alone to the exclusion of all others. Acute (intravenous) administration of propranolol lowers cardiac output and slows heart rate but does not significantly alter blood pressure. With continued therapy however, blood pressure (in responders) is gradually reduced while cardiac output and rate remains low, indicating a readaptation of total peripheral resistance (TPR) to the new haemodynamic conditions. This relatively complex interplay of factors and the predominant role of TPR in blood pressure response help explain why haemodynamic indices (such as elevated heart rate and cardiac output) were found of little value in predicting response to therapy and the failure of propranolol to control transient pressor responses associated with stress; although the increase of output in response to stress was blocked pressure rose due to increase in TPR. Therefore, despite the obvious cardiac effects of beta-adrenergic blockade, a blood pressure response to propranolol cannot be used as an index of cardiac participation in that hypertension. The long-term changes in TPR were significantly (P less than 0-02) correlated with reduction in plasma renin activity (PRA). This association does not necessarily imply a causal relationship since PRA suppression occurs at lower doses and much more rapidly than alterations in blood pressure. Further, the hypotensive effect obtained by adding propranolol to diuretic therapy was not associated with a significant reduction in PRA. However, the absence of correlation in a group of patients between blood pressure response to propranolol and its effect on other biological variables does not mean that these variables have no role in the hypotensive response. In fact, in some specific conditions the change in one variable might assume particular importance; thus in the markedly hyperkinetic circulation induced by potent vasodilators, reducing cardiac rate and output may play a major role in controlling persistent hypertension.
像高血压这种多因素疾病一样,普萘洛尔对血压的反应不能仅用一种机制来解释而排除其他所有机制。急性(静脉内)给予普萘洛尔会降低心输出量并减慢心率,但不会显著改变血压。然而,随着持续治疗,(有反应者的)血压会逐渐降低,而心输出量和心率仍保持较低水平,这表明总外周阻力(TPR)已重新适应新的血流动力学状况。这种相对复杂的因素相互作用以及TPR在血压反应中的主导作用有助于解释为什么血流动力学指标(如心率加快和心输出量增加)在预测治疗反应方面价值不大,以及普萘洛尔为何无法控制与应激相关的短暂升压反应;尽管对应激的输出增加被阻断,但由于TPR增加,血压仍会升高。因此,尽管β - 肾上腺素能阻断对心脏有明显作用,但不能将普萘洛尔对血压的反应用作心脏参与高血压的指标。TPR的长期变化与血浆肾素活性(PRA)的降低显著相关(P小于0.02)。这种关联不一定意味着存在因果关系,因为PRA抑制在较低剂量时就会发生,而且比血压变化快得多。此外,将普萘洛尔添加到利尿治疗中所获得的降压效果与PRA的显著降低无关。然而,一组患者中普萘洛尔的血压反应与其对其他生物学变量的影响之间缺乏相关性并不意味着这些变量在降压反应中不起作用。事实上,在某些特定情况下,一个变量的变化可能会变得尤为重要;因此,在强效血管扩张剂引起的明显高动力循环中,降低心率和心输出量可能在控制持续性高血压中起主要作用。